% | $
Quotes you view appear here for quick access.

NewLink Genetics Corporation Message Board

  • All I can say is most of us have no idea how much of a game changer this is. On Oct. 3, 2012 NLNK announced the launching of an open-label, randomized, multi-institutional adaptive design Phase2B/3 study to evaluate efficacy of its tergenpumatucel-L (HyperAcute┬« Lung) product candidate in patients with progressive or relapsed Stage-IIIB/IV non-small cell lung cancer (NSCLC).

    FYI the 5 year survival of Stage IIIB patients is 7% and Stage IV patients 2%. Survival rates havn't moved much over the last 50 years.

    Their Phase II study showed 21.9 vs. 7 months survival for patients that had a strong enough immune system to generate IFN-gamma responses.

    Do the math at 20M, 22, 25 M shares outstanding whatever, it matters not.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
37.14+0.64(+1.75%)Nov 25 4:00 PMEST